GenVec Announces Update of Safety and Efficacy Data from Pivotal
Phase II/III PACT Study of TNFerade at ASCO
GAITHERSBURG, Md.--(BUSINESS WIRE)--Jun 4, 2007 -
GenVec, Inc.(Nasdaq: GNVC) announced today that updated preliminary safety andefficacy data from the clinical development program of its leadproduct TNFerade(TM) was presented in a poster session ongastrointestinal cancers at the annual meeting of American Societyfor Clinical Oncology in Chicago, IL by Dr. Mitchell Posner, of theUniversity o...
GenVec Presents Research on New Ad35 Adenovector at ARVO
GAITHERSBURG, Md.--(BUSINESS WIRE)--May 10, 2007 -
GenVec, Inc.(Nasdaq:GNVC) today announced pre-clinical research demonstratingthe ability of the Company's new adenovector, Ad35, to induce andsustain protein production in the eye. Lisa L. Wei, Ph.D.,
GenVec'sDirector of Pre-Clinical Research, presented a poster, AlternateSerotype Adenovector Gives Long-Term Expression in the Eye, at theAss...
GenVec Announces New Research at AACR on Selectivity and Mechanism
of Action of TNF-Based Anti-Cancer Therapy
GAITHERSBURG, Md.--(BUSINESS WIRE)--Apr 17, 2007 -
GenVec, Inc.(Nasdaq:GNVC) announced today data from two studies presented atthe 97th annual meeting of the American Association of CancerResearch (AACR) that further support the use of adenovector systemsto deliver the gene for tumor necrosis factor-alpha (TNF(alpha)).
GenVec's lead product candidate, TNFerade(TM) biologic (TNFerade)is an ad...